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South Africa was being targeted as the
first recipient of some of the Bush
administration’s R120 billion global
commitment to fight AIDS and should
‘jump in with both feet’ to consolidate
its position.
This was the tip from Professor Roy
Anderson, one of the world’s top AIDS
researchers and head of the department
of Infectious Disease Epidemiology at
the Faculty of Medicine at London
University’s Imperial College.
Speaking to the SAMJ at the Durban
conference on ‘Empirical Evidence for
the Demographic and Socio-Economic
Impact of AIDS’ at the end of March,
Anderson said that the United States
Department of Health had custody of
the grant. This was because the WHO,
UNAIDS and the World Bank were
unable to reach agreement over who
should distribute the money.
Two delegates from the US State
Department attended the Durban AIDS
conference to update themselves on the
latest evidence on the pandemic in this
country - which Anderson said was
further proof that SAwas the top
prospective recipient. 
‘The feeling is that SAshould be the
first to receive - if your government
accepts. The delicacy of course is how it
is spent. I think the USAis very keen
that some of it is spent on anti-
retrovirals (ARV)’.
Anderson  was described by
Professor Alan Whitehead, director of
the Health Economics and HIV/AIDS
Research Division (HEARD) at the
University of Natal (which organised
the conference)  as the world’s ‘most
consistently accurate person on
HIV/AIDS projections’.
Anderson continued by saying that
because of AIDS, South Africa,
Botswana and Zimbabwe would for the
first time this year experience negative
population growth ranging from -0.1 to
-0.3. Without AIDS, growth rates would
have been between 1.1 and 2.3.
Five other countries in sub-Saharan
Africa would experience growth rates of
nearly zero.Were it not for AIDS they
would have had population growth
rates of two per cent or greater.
‘It’s quite extraordinary how the
world ignores this problem -
interventions cost such a small amount
of money when you consider that it is
the largest and most lethal epidemic in
history with 42 million people infected’.
Anderson added that several African
leaders in the sub-Saharan region
needed ‘a heavy dose of reality’.
Asked how he and his peers in the
international scientific community
viewed the South African government’s
response to the pandemic he said most
were ‘very puzzled at your political
leadership’. He cited the recent
appointment of AIDS dissident, Dr
Roberto Giraldo as a nutritional advisor
to Health Minister Dr Manto
Tshabalala-Msimang:
‘Colleagues I talk to throw up their
hands and look at the sky...you’re one of
the countries with the worst problem’.
While he understood President
Mbeki’s contention that AIDS was a
disease of poverty, if Nelson Mandela
was still in power ‘he would be on the
radio and television daily pushing the
ABC message’.
‘This has to be a (political) priority,
otherwise you’ll lose half your
population,’ he warned. 
The lion’s share of research funding
needed to go into vaccines of which
even an imperfect variety slowed HIV-
positive progression towards AIDS and
lowered infectiousness towards
susceptible sexual partners.
Licensing imperfect vaccines however
could prove to be a major task and the
US Food and Drug Administration
(FDA) had to be persuaded to ‘take a
long, hard look at this’.
It was ‘crucial’ to encourage the
biggest but sometimes reluctant
pharmaceutical companies to continue
and enhance investment in this field.
Glaxo, for example, had reduced its
investment to ‘exceedingly low’ levels.
‘We have a responsibility to persuade
them to stay in this very difficult area’.
One danger of imperfect vaccines was
that vaccination could be linked to
increased risk behaviours.
The recent plateau of HIV prevalence
among people under 20 in South Africa
showed that spending on the ABC of
prevention was effective and at least as
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important as providing antiretroviral
therapy (ART).
Anderson’s most emphatic message
to physicians and nurses was that they
should ensure patients’ compliance with
ARV drug regimens. ARV drugs held
proven benefits for the individual
patient, communities and women in the
later stages of pregnancy and were ‘a
humanitarian necessity’ because they
improved the quality of life of people
living with AIDS (PWAs) ‘enormously’.
‘Most physicians, whether they’re
First or Third World, don’t truly
understand the importance of
adherence. I cannot think of a virus
where adherence is more important.
Most of us are pretty lax around
antibiotics and the like, but with HIV it
matters enormously because the virus
mutates so quickly’. In one AIDS patient
with 10 to the power 10 of viral
particles, every mutation across the
entire genome was possible every day.
‘You simply cannot afford to miss a
day of taking these drugs. Any slight
concentration drop creates the ideal
circumstances where more resistance
develops’.
Anderson said 80% of resistance to
ARVs that emerged in Europe and the
USAwas due to poor adherence.
ART’s greatest benefit for the
community was that it lowered the
overall community viral load and thus
susceptibility to the disease.
Intervention with sex workers
worked best in the first five to 10 years
of the epidemic, after which the focus
had to shift to community-based
interventions. The classic epidemic
spread was from sex workers to men to
pregnant women.
Anderson said South Africa was the
only country in Africa that had the
capacity to manufacture protease
inhibitors - by far the most effective
ARV drug - and urged the government
and private sector to do all that it could
to make this happen.
‘I’d like to see this happen in South
Africa, India, South Korea and perhaps
Thailand - it’s not that difficult to
manufacture these drugs, the problem is
ensuring safety and quality. If it’s not
up to scratch, it’ll be the quickest to
develop drug resistance’.
Recent studies of human genetics had
shown that our genomes and the
genetic diversity within populations
reflected our past experience of major
epidemics.
What made AIDS different, and in
many specialists’ minds more
threatening than past pandemics, was
its potential to influence human
demography.
Another major difference was that the
case-related death rate was 90-100% of
those infected in the absence of
treatment, compared with history’s next
worst disease, the plague which killed
30 - 40% of the young and elderly who
were infected.
Chris Bateman
Ongoing safety and efficacy research on
traditional African medicines at the
MRC points to at least one compound
being responsible for dramatic weight
gain, a drop in viral loads and increased
CD4 cell counts among AIDS patients.
Still in the very early stages of testing,
the compound, which originates from
the North West Province, is being kept a
closely guarded secret because of
intellectual property rights.
Dr Gilbert Matsabisa, head of
Indigenous Knowledge Systems at the
MRC, told the SAMJ that 30 test
patients, some of whom were unable to
walk and others who suffered from
acute pneumonia, oral thrush and
diarrhoea showed major improvement
AGE OLD REMEDY IMPACTS HIV - MRC
Anderson added that several
African leaders in the sub-
Saharan region needed ‘a
heavy dose of reality’.
The MRC says some traditional remedies have remarkable immune-boosting properties.
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